Citigroup Maintains Buy on Beam Therapeutics, Raises Price Target to $68

Citigroup analyst Samantha Semenkow has maintained a 'Buy' rating on Beam Therapeutics (NASDAQ: BEAM) and increased the price target from $64 to $68. This adjustment reflects a positive outlook for the company's stock performance.